IGF2 and neoplasm: Notably, IGF2 de-regulation cannot be assessed by merely probing the mutation landscape of the tumor, which renders scRNAseq of CTCs an outstanding tool to detect non-mutated druggable genomic aberrations such as IGF2 overexpression.